Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction.
SMCypI C31 exerts at least additive antiviral effects when combined with the NS5A inhibitor ledipasvir and is fully active against ledipasvir-resistant viruses.
SMCypI C31 also inhibits the replication of other members of the Flaviviridae family (DENV EC50=7.3 uM), YFV EC50, 27.2 uM, and ZIKV EC50=48.0 uM), without significant cytotoxicity.
